Uracil-DNA glycosylase in benign and malignant maturing human hematopoietic cells.
The expression of uracil-DNA glycosylase was studied in human normal hematopoietic bone marrow cells and in malignant counterparts obtained from patients with chronic granulocytic leukemia. We observed that the expression of the enzyme was highest in the proliferating granulocytic compartment (myeloblasts through myelocytes) and that it was diminished in more mature cells. Furthermore, we demonstrated that uracil-DNA glycosylase activity was higher in immature red blood cells or reticulocytes than in more mature red cells. The same tendency was also demonstrated in human malignant monoblasts, which were induced to terminal maturation by phorbol ester. It can be concluded from these results that uracil-DNA glycosylase expression is equal in benign and malignant hematopoietic progenitor cells; no selectivity towards malignant vs. benign progenitors can be expected in possible chemotherapeutic approaches relying on uracil-DNA glycosylase.
D002470:Cell Survival; D045647:DNA Glycosylases; D006412:Hematopoietic Stem Cells / Q000201:enzymology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000201:enzymology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000201:enzymology; D009699:N-Glycosyl Hydrolases / Q000097:blood*; D012156:Reticulocytes / Q000201:enzymology; D013755:Tetradecanoylphorbol Acetate; D051981:Uracil-DNA Glycosidase
D045647:DNA Glycosylases; D009699:N-Glycosyl Hydrolases; D051981:Uracil-DNA Glycosidase; D013755:Tetradecanoylphorbol Acetate